Marcus Scott
Medical · Pierceton, INNPI 1326271677
Payments from drug & device makers
Across 135 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$612
- AstraZeneca$263
- Novo Nordisk$199
- GSK$157
- Boehringer Ingelheim$105
- Axsome Therapeutics, Inc.$105
- plus $649 from 15 others
What the payments were for
- Food & beverage$2,089100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 50 | $612 |
| AstraZeneca | 15 | $263 |
| Novo Nordisk | 13 | $199 |
| GSK | 9 | $157 |
| Boehringer Ingelheim | 6 | $105 |
| Axsome Therapeutics, Inc. | 4 | $105 |
| Amgen | 7 | $99 |
| Pfizer | 3 | $85 |
| Sanofi-aventis U.S. LLC | 5 | $77 |
| Johnson & Johnson | 3 | $59 |
| Astellas Pharma US Inc | 3 | $52 |
| Abbott | 3 | $49 |
| Amarin Pharma, Inc. | 2 | $39 |
| Exact Sciences | 2 | $39 |
| Lilly USA, LLC | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Merck | 2 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$2,089 in reported general payments places this provider in the 75th percentile of 273 medical providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $106,678 |
| JardianceEmpagliflozin | 53 | $72,225 |
| OzempicSemaglutide | 32 | $52,552 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $50,134 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $36,903 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $32,063 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 65 | $29,266 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $26,894 |
| MounjaroTirzepatide | 15 | $24,437 |
| Victoza 3-PakLiraglutide | 12 | $23,056 |
| LinzessLinaclotide | 20 | $20,480 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $19,581 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $19,453 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $17,281 |
| FarxigaDapagliflozin Propanediol | 15 | $15,299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $85 | $106,678134 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $157 | $96,681139 claims |
| Boehringer IngelheimJardiance, Tradjenta | $105 | $78,41665 claims |
| Novo NordiskOzempic | $199 | $52,55232 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $263 | $37,92759 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $77 | $32,06318 claims |
| Lilly USA, LLCMounjaro | $34 | $24,43715 claims |
| AbbVieLinzess | $612 | $20,48020 claims |
| Johnson & JohnsonInvokana | $59 | $6,43011 claims |
| MerckJanuvia | $24 | $6,39912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 273 medical providers in Indiana.
Other medical in Pierceton
- Meggie BeckleyIndianapolis$125K
- Jennifer ConnerIndianapolis$98K
- Brandon BoydCarmel$46K
- Karey DavisNew Castle$45K
- Sheryl NewCarmel$39K
- Lindsey GradyValparaiso$39K
- Jennifer IrwinIndianapolis$34K
- Dennae DaltonZionsville$33K
- Jenifer FortneyFort Wayne$26K
- Jordan Stemer-MirandaCrown Point$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.